Roche introduces new GS FLX+ software for significantly improved long-read sequencing performance
First high-throughput sequencing platform to deliver one million reads with read lengths of up to 1000 bp and beyond
"This latest software release represents a major step forward in meeting the expectations of our customers on the long-read performance of the GS FLX+ System," said Thomas Schinecker, President Roche Sequencing Solutions. "Over 30 leading sequencing laboratories around the world are already implementing the latest improvements of our new software, and their feedback has been overwhelmingly positive."
Since the launch of the GS FLX+ System, researchers have confirmed the value of extra-long reads
for more complete de novo assembly of whole genomes, superior full-length transcriptome analysis, and better characterization of mixed metagenomic samples. The latest software will further improve the sequencing results for these applications and also bring new functionality enhancements to the suite of 454 Sequencing System's bioinformatics tools for de novo assembly, mapping, and variant analysis.
"We have experienced excellent results in our laboratory using the latest GS FLX+ software. All sequencing metrics, including read length, have exceeded our expectations," explained Hiroshi Tarui, RIKEN Omics Science Center and Yokohama City University KIHARA Institute for Biological Research. "We are excited to use the platform in our de novo transcriptome studies, where the long reads are critical for full-length assembly of cDNA transcripts and splice variant investigation."
"We have been using the GS FLX+ System extensively for our de novo sequencing project of different tobacco strains achieving modal read lengths of around 820 bases and several runs with an output of more than 1 Gb," said Bernd Timmermann, Head of the Max Planck Institute Sequencing Core Facility, Berlin, Germany. "With the upgrade to the v2.8 software, we are seeing an improvement in average and modal read length in all cases. We will continue to use our GS FLX+ Systems in the future for our de novo sequencing and metagenome projects."
Roche also plans to roll out long-read improvements for long amplicon sequencing on the GS FLX+ System. They will advance sequencing results for targeted sequencing and 16S/18S rRNA metagenomic applications. For additional information and user feedback on the latest improvements to the GS FLX+ System, please visit www.454.com/seewhatspossible.
Roche Diagnostics Deutschland GmbH
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
Press releases you might also be interested in
Weitere Informationen zum Thema "Forschung und Entwicklung":
Intel zeigt Ausblick auf die künstliche Intelligenz von morgen
Welche Veränderungen, die künstliche Intelligenz zukünftig für uns alle bringen wird, konnte man in diesem Jahr auf der größten Konsumenten-Elektronikmesse der Welt, der CES in Las Vegas sehen. Auch am Stand von Intel gab es vieles zu sehen. Angefangen vom Autonomen Fahren, bis hin zu den Möglichkeiten, die die Virtuelle Realität bietetWeiterlesen